RxDoctor Payments Data

Benjamin Frizner, MD

Internal Medicine · Pikesville, MDNPI 1083633317

Payments from drug & device makers

$368in general payments, 2019–2025

Across 5 payments — averaging $73.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$141
  • Boehringer Ingelheim$111
  • Philips North America LLC$94
  • Otsuka America Pharmaceutical, Inc.$21

What the payments were for

  • Food & beverage$368100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$368 in reported general payments places this provider in the 60th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$628,814
Medicare patients
559
Services billed
7,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala20$85,041
EliquisApixaban166$65,986
TivicayDolutegravir Sodium13$31,290
SantylCollagenase Clostridium Hist.12$27,674
NuedextaDextromethorphan Hbr/Quinidine11$16,911
VraylarCariprazine Hcl26$16,587
OxycontinOxycodone Hcl37$12,157
JardianceEmpagliflozin35$11,800
XareltoRivaroxaban24$11,647
Levetiracetam198$9,191
Arformoterol Tartrate28$8,169
ErtapenemErtapenem Sodium27$7,953
Atorvastatin Calcium373$7,239
Budesonide72$7,186
TrulicityDulaglutide21$6,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$141$16,91111 claims
Boehringer IngelheimJardiance$111$11,80035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Pikesville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →